Other · Immune activation · developed by TuHURA Biosciences
IFx-Hu2.0 (pAc/emm55) is an innate immune agonist given intralesionally. It is being studied in advanced or metastatic Merkel cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06947928 | Phase 2/3 | Advanced Or Metastatic Merkel Cell Carcinoma | Recruiting | HURA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Or Metastatic Merkel Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the HURA page.
See HURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HURA catalysts and pipeline →